Alto Neuroscience (ANRO) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alto Neuroscience (ANRO) has outperformed Omeros (OMER) over the past year, gaining 91.5% versus a gain of 48.9%. Alto Neuroscience is the larger company by market cap ($1.02 billion vs $983.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANRO | OMER |
|---|---|---|
| Share price | $25.37 | $13.21 |
| Market cap | $1.02B | $983.66M |
| 1-day change | -4.30% | -5.71% |
| YTD return | +42.53% | -23.11% |
| 1-year return | +91.47% | +48.93% |
| 5-year return | — | +77.79% |
| P/E ratio (TTM) | — | 15.92 |
| Forward P/E | — | 11.95 |
| EPS (TTM) | $-2.32 | $0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-63.24M | $-3.35M |
| 52-week high | $37.48 | $21.24 |
| 52-week low | $12.51 | $6.70 |
| Distance from 52-week high | -32.31% | -37.81% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +52.42% | +108.18% |
| Average volume | 614.92K | 1.36M |
| Shares outstanding | 40.11M | 74.46M |
| Employees | 68 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANRO has outperformed OMER by 42.5 percentage points over the past year.
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
ANRO vs OMER FAQ
Which is bigger, Alto Neuroscience or Omeros?
Alto Neuroscience (ANRO) is larger, with a market capitalization of $1.02B compared with $983.66M for Omeros (OMER).
Which stock has performed better over the past year, ANRO or OMER?
ANRO returned +91.47% over the past 12 months, compared with +48.93% for OMER (price return, excluding dividends). Past performance does not predict future results.
Are Alto Neuroscience and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.